Experimental cisplatin neuronopathy in rats and the effect of retinoic acid administration

被引:53
作者
Tredici, G
Tredici, S
Fabbrica, D
Minoia, C
Cavaletti, G
机构
[1] Univ Milan, Ist Anat Umana, Milan, Italy
[2] Univ Milan, Clin Neurol 5, Monza, Italy
[3] IRCCS, Clin Lavoro Riabilitaz, Fondaz S Maugeri, Pavia, Italy
关键词
cisplatin neuronopathy; dorsal root ganglia; nerve conduction velocity; retinoic acid; neuroprotection; nerve recovery;
D O I
10.1023/A:1005756023082
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Peripheral nervous system alterations were induced in adult rats by administration of cisplatin (CDDP) 2 mg/kg twice weekly for 4.5 weeks. Dorsal root ganglion neurons showed pathological changes. Morphometric determinations demonstrated a reduction in size of the somatic, nuclear and nucleolar area. The nucleoli were the most involved subcellular structures. Nerve conduction velocity and the tail-flick test for pain were both significantly altered in CDDP treated rats, whereas the rota-rod test for coordination revealed no changes in either treated or control rats. Analytical determinations demonstrated platinum accumulation in the DRG of CDDP treated rats. Spontaneous recovery, demonstrated by morphometric, electrophysiological, functional and analytical determinations, occurred after treatment discontinuation within about 7 weeks. A pilot study of the possible neuroprotective action of retinoic acid (RA) was also performed with this model of cisplatin neuronopathy. The rationale for using RA was based on its assumed antioxidant and neurotrophic effect. However, RA failed to prevent morphometric, electrophysiological, functional and analytical alterations induced by CDDP on DRG neurons. RA induced only a mild generalized protective effect.
引用
收藏
页码:31 / 40
页数:10
相关论文
共 59 条
[1]   PERMEATION OF PROTEINS FROM THE BLOOD INTO PERIPHERAL-NERVES AND GANGLIA [J].
ALLEN, DT ;
KIERNAN, JA .
NEUROSCIENCE, 1994, 59 (03) :755-764
[2]   NERVE GROWTH-FACTOR PREVENTS EXPERIMENTAL CISPLATIN NEUROPATHY [J].
APFEL, SC ;
AREZZO, JC ;
LIPSON, L ;
KESSLER, JA .
ANNALS OF NEUROLOGY, 1992, 31 (01) :76-80
[3]   Neuropeptides and morphological changes in cisplatin-induced dorsal root ganglion neuronopathy [J].
Barajon, I ;
Bersani, M ;
Quartu, M ;
DelFiacco, M ;
Cavaletti, G ;
Holst, JJ ;
Tredici, G .
EXPERIMENTAL NEUROLOGY, 1996, 138 (01) :93-104
[4]   LACK OF LATE TOXICITY IN PATIENTS TREATED WITH CISPLATIN-CONTAINING COMBINATION CHEMOTHERAPY FOR METASTATIC TESTICULAR CANCER [J].
BOYER, M ;
RAGHAVAN, D ;
HARRIS, PJ ;
LIETCH, J ;
BLEASEL, A ;
WALSH, JC ;
ANDERSON, S ;
TSANG, CS .
JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (01) :21-26
[5]   THE POTENTIAL FOR TREATING NEURODEGENERATIVE DISORDERS WITH NGF-INDUCING COMPOUNDS [J].
CARSWELL, S .
EXPERIMENTAL NEUROLOGY, 1993, 124 (01) :36-42
[6]   NEUROPROTECTIVE EFFECT OF REDUCED GLUTATHIONE ON CISPLATIN-BASED CHEMOTHERAPY IN ADVANCED GASTRIC-CANCER - A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL [J].
CASCINU, S ;
CORDELLA, L ;
DELFERRO, E ;
FRONZONI, M ;
CATALANO, G .
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (01) :26-32
[7]   TISSUE PLATINUM CONCENTRATIONS AND CISPLATIN SCHEDULES [J].
CAVALETTI, G ;
TREDICI, G ;
PIZZINI, G ;
MINOIA, A .
LANCET, 1990, 336 (8721) :1003-1003
[8]  
CAVALETTI G, 1992, CANCER-AM CANCER SOC, V69, P203, DOI 10.1002/1097-0142(19920101)69:1<203::AID-CNCR2820690133>3.0.CO
[9]  
2-1
[10]  
CAVALETTI G, 1992, ACTA NEUROPATHOL, V84, P364